{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:30:42Z","timestamp":1787121042272,"version":"build-2736575974"},"reference-count":27,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Weight loss is a well-documented adverse effect of psychostimulants. Given their frequent coprescription with second-generation antipsychotics (SGA) in pediatric patients, this study aims to examine whether concomitant use of psychostimulants mitigates SGA-associated weight gain in children and adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>\n                      This study utilized the IQVIA Ambulatory electronic medical record-U.S. database (2016\u20132021) to identify patients aged 6\u201317 years who initiated an SGA. Those who started psychostimulants within 7 days of SGA initiation and maintained \u226590 days of use were classified as concomitant users, while those who initiated psychostimulants later with \u226590 days of overlap were add-on users. Patients never prescribed psychostimulants were SGA-only users. After adjusting for the baseline covariates using propensity scores, 6- and 12-month body mass index (BMI)\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      -score trends following psychostimulant initiation were compared between (1) concomitant and SGA-only users and (2) add-on and SGA-only users, using a linear mixed-effects regression model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The results of linear mixed effect regression models indicate that concomitant users experienced a 0.0143 less monthly BMI\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      -score increase (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.0063) compared with the SGA-only users over the 6 months following psychostimulant initiation. Similarly, add-on users had a significantly lower rate of weight gain compared with SGA-only users (\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      = \u22120.0463,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.0001). When the follow-up period was extended to 12 months, the sensitivity analyses for both concomitant and add-on users were consistent with their primary analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Concomitant and add-on psychostimulants appear to mitigate SGA-associated weight gain in children and adolescents. Further investigation is needed to understand their effectiveness and safety relative to other interventions for antipsychotic-associated weight gain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2024.0135","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T12:23:16Z","timestamp":1744633396000},"page":"508-517","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Does Concomitant Psychostimulants Mitigate Second-Generation Antipsychotics-Associated Weight Gain? An Observational Study Based on Electronic Medical Records Data"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2844-4685","authenticated-orcid":false,"given":"Ning","family":"Lyu","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Houston, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Rowan","sequence":"additional","affiliation":[{"name":"School of Public Health, The University of Texas at Houston, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Varisco","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Houston, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Abughosh","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Houston, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lin","sequence":"additional","affiliation":[{"name":"College of Engineering, University of Houston, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7889-8023","authenticated-orcid":false,"given":"Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Houston, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013337.PUB2"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/1044546041649020"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/CAP.2008.007"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23M14894"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAAC.2023.02.017"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.2307\/2683591"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.CHI.0000220851.94392.30"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.MOLMED.2010.10.010"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/NRENDO.2011.156"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1542\/PEDS.100.4.662"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/APA.15881"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAPSYCHIATRY.2015.2923"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017490"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAAC.2014.05.010"},{"issue":"246","key":"e_1_3_3_16_1","first-page":"1","article-title":"2000 CDC growth charts for the United States: Methods and development","volume":"11","author":"Kuczmarski RJ","year":"2002","unstructured":"Kuczmarski RJ, , Ogden CL, , Guo SS, et al. 2000 CDC growth charts for the United States: Methods and development. Vital Health Stat 11, 2002; 11(246):1\u2013190.","journal-title":"Vital Health Stat 11"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001814"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/CAP.2023.0071"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/ARCHPEDI.162.10.929"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.SAPHARM.2018.06.005"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.2478\/PRILOZI-2018-0013"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/IJE\/30.6.1332"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/CAP.2016.0133"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.SCHRES.2010.07.012"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1542\/PEDS.2013-3427"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2016.3611"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00787-020-01614-4"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwi307"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2024.0135","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2024.0135","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2024.0135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:18:27Z","timestamp":1787120307000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2024.0135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11,1]]}},"alternative-id":["10.1089\/cap.2024.0135"],"URL":"https:\/\/doi.org\/10.1089\/cap.2024.0135","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}